Clean Science and Technology Limited — Investor Meet, 19-07-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Clean Science & Technology: Q1 FY26 standalone revenue hit 217 Cr, but record 46% EBITDA margin (101 Cr) driven by strong established product volumes. Consolidated sales stood at 240 Cr. Despite global volatility impacting non-established products, HALS sales (24 Cr) are nearing breakeven, with higher-margin grades coming soon. 80 Cr capex on track for Performance Chemical 1 (Q2 commercialization) and 2 (Q4 FY26). FY26 EBITDA growth outlook adjusted to 15-18%, with Q2 likely softer, pickup in Q3/Q4. Promoter stake to reduce from 75% to 51% due to estate planning. Management is confident about new products and margin expansion.